Sundus Sardar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sundus Sardar has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
Nasrollah Ghahramani
Department of Nephrology Penn State Milton S. Hershey Medical Center Hershey USA
18 shared publications- Ahmad Matarneh
Department of Nephrology Penn State Milton S Hershey Medical Center Hershey Pennsylvania USA
13 shared publications - Omar Salameh
University Health Truman Medical Center Kansas City Missouri USA
10 shared publications Navin Verma
Department of Nephrology Penn State Milton S Hershey Medical Center Hershey Pennsylvania USA
9 shared publicationsNaman Trivedi
Department of Nephrology Penn State Milton S. Hershey Medical Center Hershey USA
7 shared publicationsRonald Miller
Penn State Health Milton S Hershey Medical Center
7 shared publications
Latest Publications
- Open Access
- 14 April 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (4)
Immune Checkpoint Inhibitor‐Induced Endocrine Dysfunction: Early Detection of Symptoms and Timely Intervention
Immune checkpoint inhibitors (ICI) target immune regulatory pathways to enhance antitumor responses. Although these agents improve survival, they can cause immune‐related adverse events (irAEs). Hypophysitis is a recognized irAE—particularly with CTLA‐4 inhibitors—but this case is notable for occurring in an elderly patient receiving combination therapy and presenting with nonspecific symptoms that mimicked cancer‐related fatigue and treatment side effects. We report a 76‐year‐old woman on ICI therapy who developed intractable back pain, nausea, and severe hyponatremia, ultimately diagnosed with ICI‐induced hypophysitis. Her evaluation revealed multiple electrolyte abnormalities, secondary adrenal insufficiency, and pituitary enlargement on magnetic resonance imaging (MRI), necessitating urgent fluid resuscitation and corticosteroid replacement. As use of ICIs expands across malignancies, understanding the side effect profile and atypical or subtle presentations is essential in providing prompt diagnosis and treatment of sequelae that can mimic autoimmune diseases. It underscores diagnostic complexity in real‐world settings and the need for heightened awareness of adverse endocrine events, especially in older patients and those receiving sequential or combination regimens. Careful monitoring of irAEs allows for irAEs risk mitigation and improves patient tolerability in continuing ICI cancer treatment. Clinicians should maintain a high index of suspicion and implement appropriate monitoring protocols for early detection.
- 14 April 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (4)
Open AccessImmune Checkpoint Inhibitor‐Induced Endocrine Dysfunction: Early Detection of Symptoms and Timely Intervention
Immune checkpoint inhibitors (ICI) target immune regulatory pathways to enhance antitumor responses. Although these agents improve survival, they can cause immune‐related adverse events (irAEs). Hypophysitis is a recognized irAE—particularly with CTLA‐4 inhibitors—but this case is notable for occurring in an elderly patient receiving combination therapy and presenting with nonspecific symptoms that mimicked cancer‐related fatigue and treatment side effects. We report a 76‐year‐old woman on ICI therapy who developed intractable back pain, nausea, and severe hyponatremia, ultimately diagnosed with ICI‐induced hypophysitis. Her evaluation revealed multiple electrolyte abnormalities, secondary adrenal insufficiency, and pituitary enlargement on magnetic resonance imaging (MRI), necessitating urgent fluid resuscitation and corticosteroid replacement. As use of ICIs expands across malignancies, understanding the side effect profile and atypical or subtle presentations is essential in providing prompt diagnosis and treatment of sequelae that can mimic autoimmune diseases. It underscores diagnostic complexity in real‐world settings and the need for heightened awareness of adverse endocrine events, especially in older patients and those receiving sequential or combination regimens. Careful monitoring of irAEs allows for irAEs risk mitigation and improves patient tolerability in continuing ICI cancer treatment. Clinicians should maintain a high index of suspicion and implement appropriate monitoring protocols for early detection.
- Open Access
- 20 March 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (3)
Renal‐Limited Thrombotic Microangiopathy due to Anti‐ VEGF / TKI Immunotherapy for Metastatic Renal Cell Carcinoma Presenting as Nephrotic Syndrome: A Case Report and Literature Review
Vascular endothelial growth factor (VEGF) inhibition may result in proteinuria, worsening hypertension, chronic kidney injury, or glomerular disease. Recently, systemic VEGF inhibition has been reported to cause nephrotic disorders and thrombotic microangiopathy (TMA). We present a unique case of renal‐limited TMA presenting as nephrotic syndrome in a patient on anti‐VEGF/TKI immunotherapy and immune checkpoint inhibitors for metastatic renal cell carcinoma.
- 20 March 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (3)
Open AccessRenal‐Limited Thrombotic Microangiopathy due to Anti‐ VEGF / TKI Immunotherapy for Metastatic Renal Cell Carcinoma Presenting as Nephrotic Syndrome: A Case Report and Literature Review
Vascular endothelial growth factor (VEGF) inhibition may result in proteinuria, worsening hypertension, chronic kidney injury, or glomerular disease. Recently, systemic VEGF inhibition has been reported to cause nephrotic disorders and thrombotic microangiopathy (TMA). We present a unique case of renal‐limited TMA presenting as nephrotic syndrome in a patient on anti‐VEGF/TKI immunotherapy and immune checkpoint inhibitors for metastatic renal cell carcinoma.
- Open Access
- 12 February 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (2) , e72055
Leukocyte Chemotactic Factor 2 Amyloidosis ( LECT ‐2) Amyloidosis Case Report and Review of the Current Literature
Amyloid deposition is an increasingly recognized contributor to chronic kidney disease and end‐stage renal disease. It can result from various underlying conditions, including monoclonal gammopathies and chronic inflammatory states. Diagnosis is typically established by kidney biopsy demonstrating characteristic amyloid deposits. ALECT2 (leukocyte chemotactic factor 2) amyloidosis can present as nephrotic‐range proteinuria. ALECT2 amyloidosis is an uncommon and under‐recognized.
- 12 February 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (2) , e72055
Open AccessLeukocyte Chemotactic Factor 2 Amyloidosis ( LECT ‐2) Amyloidosis Case Report and Review of the Current Literature
Amyloid deposition is an increasingly recognized contributor to chronic kidney disease and end‐stage renal disease. It can result from various underlying conditions, including monoclonal gammopathies and chronic inflammatory states. Diagnosis is typically established by kidney biopsy demonstrating characteristic amyloid deposits. ALECT2 (leukocyte chemotactic factor 2) amyloidosis can present as nephrotic‐range proteinuria. ALECT2 amyloidosis is an uncommon and under‐recognized.
- Open Access
- 17 January 2026
- Published by Wiley
Correction to ‘Resumption of Peritoneal Dialysis Postpartum Following Pregnancy in an ESRD Patient: A Case Report and Literature Review’
- 17 January 2026
- Published by Wiley
Open AccessCorrection to ‘Resumption of Peritoneal Dialysis Postpartum Following Pregnancy in an ESRD Patient: A Case Report and Literature Review’
- Open Access
- 20 November 2025
- Published by Wiley
An Unusual Case of Allergic Interstitial Nephritis: Potential Exacerbation by Tazemetostat in the Context of Ifosfamide Therapy and literature review
- 20 November 2025
- Published by Wiley
Open AccessAn Unusual Case of Allergic Interstitial Nephritis: Potential Exacerbation by Tazemetostat in the Context of Ifosfamide Therapy and literature review
- Open Access
- 17 November 2025
- Published by Wiley
ALECT-2 Amyloidosis case report and review of the current literature
- 17 November 2025
- Published by Wiley
Open AccessALECT-2 Amyloidosis case report and review of the current literature
- Open Access
- 12 October 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (10)
Resumption of Peritoneal Dialysis Postpartum Following Pregnancy in an ESRD Patient: A Case Report and Literature Review
Temporary transition from peritoneal to hemodialysis during pregnancy does not need to be permanent. When catheter patency and membrane function are preserved, peritoneal dialysis can be safely resumed postpartum. This case reinforces the importance of individualized, multidisciplinary dialysis management to optimize maternal and fetal outcomes in pregnant ESRD patients.
- 12 October 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (10)
Open AccessResumption of Peritoneal Dialysis Postpartum Following Pregnancy in an ESRD Patient: A Case Report and Literature Review
Temporary transition from peritoneal to hemodialysis during pregnancy does not need to be permanent. When catheter patency and membrane function are preserved, peritoneal dialysis can be safely resumed postpartum. This case reinforces the importance of individualized, multidisciplinary dialysis management to optimize maternal and fetal outcomes in pregnant ESRD patients.
- Open Access
- 27 July 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (8) , e70665
Spurious Hyperphosphatemia From Alteplase‐Treated Catheter: A Case Report and Literature Review
Falsely elevated phosphate levels can occur when blood is drawn after alteplase use in dialysis catheters due to phosphorus‐containing excipients. Recognizing spurious hyperphosphatemia is important to prevent misdiagnosis, avoid inappropriate treatment changes, and ensure accurate phosphate monitoring in patients undergoing maintenance hemodialysis.
- 27 July 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (8) , e70665
Open AccessSpurious Hyperphosphatemia From Alteplase‐Treated Catheter: A Case Report and Literature Review
Falsely elevated phosphate levels can occur when blood is drawn after alteplase use in dialysis catheters due to phosphorus‐containing excipients. Recognizing spurious hyperphosphatemia is important to prevent misdiagnosis, avoid inappropriate treatment changes, and ensure accurate phosphate monitoring in patients undergoing maintenance hemodialysis.